Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Chemomab Therapeutics Ltd. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +5 vs. Q3 2023
- Shares held
- 2.81M
- +283.2K (+11.2%) vs. Q3 2023
- Total value
- $1.43M
- −$830.0K (−36.6%) vs. Q3 2023
- New holders
- 7
- 1 more added
- Sold out
- 2
- 1 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $615.3K |
| Q1 2026 | 15 | $551.9K |
| Q4 2025 | 14 | $606.1K |
| Q3 2025 | 10 | $1.03M |
| Q2 2025 | 14 | $4.91M |
| Q1 2025 | 17 | $4.07M |
| Q4 2024 | 16 | $7.53M |
| Q3 2024 | 15 | $7.14M |
| Q2 2024 | 15 | $2.44M |
| Q1 2024 | 14 | $2.07M |
| Q4 2023 | 16 | $1.43M |
| Q3 2023 | 11 | $2.26M |
| Q2 2023 | 11 | $3.33M |
| Q1 2023 | 13 | $4.56M |
| Q4 2022 | 14 | $10.6M |
| Q3 2022 | 15 | $8.09M |
| Q2 2022 | 13 | $12.2M |
| Q1 2022 | 15 | $15.9M |
| Q4 2021 | 14 | $22.7M |
| Q3 2021 | 15 | $35.9M |
| Q2 2021 | 12 | $58.7M |
| Q1 2021 | 10 | $82.6M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Chemomab Therapeutics Ltd.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 2,241,274 | $1.14M | 0.02% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 213,392 | $108.8K | 0.03% | 00.0% | Unchanged |
| Morgan Stanley | 70,915 | $36.2K | 0.00% | +70,915 | New |
| Two Sigma Investments, LP | 56,305 | $28.7K | 0.00% | +56,305 | New |
| Two Sigma Advisers, LP | 35,400 | $18.1K | 0.00% | +35,400 | New |
| Citadel Advisors LLC | 32,677 | $16.7K | 0.00% | +32,677 | New |
| Kestra Private Wealth Services, LLC | 31,241 | $15.9K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 29,047 | $14.8K | 0.00% | +29,047 | New |
| Boothbay Fund Management, LLC | 26,529 | $13.5K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 25,808 | $13.0K | 0.00% | +25,808 | New |
| Millennium Management LLC | 19,701 | $10.0K | 0.00% | +19,701 | New |
| Rhumbline Advisers | 18,627 | $9.50K | 0.00% | +15,784+555.2% | Added |
| Geode Capital Management, LLC | 11,737 | $5.99K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 585 | $297 | 0.00% | −1,190−67.0% | Reduced |
| Moser Wealth Advisors, LLC | 500 | $255 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 44 | $22 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −1,100−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −141−100.0% | Sold out |